Medistim ASA has transferred 9.000 shares to Medistim CEO, Kari E. Krogstad, at
the last traded share price in 2023, of 214 NOK per share. This is in accordance
with her compensation agreement with the company, as described in the Company's
Annual Report. After the transfer, Kari E. Krogstad holds a total of 47.083
shares.

According to the CEO's share program she is entitled to receiving another 7.500
shares if in position 1st of January 2025 and another 8.000 shares if in
position 1st of January 2026. A new agreement is entered between the company and
the CEO, related to this share program. The CEO 100% owned company, K2
Consulting AS, has purchased the shares from Medistim ASA with a lock in period
of 1 year for the 7.500 shares and a lock in period of 2 years for the 8.000
shares. The lock in period of 1 year qualifies for a 14 % share price discount
and the 2 year lock in period qualifies for an 18% discount. Average share price
in the 14 days subscription period was NOK 216 per share. 7.500 shares was
therefore purchased at NOK 185,83 per share and 8.000 shares was purchased at
NOK 177,19 per share. To finance the purchase, Medistim has given the CEO a loan
and when the lock in period has ended, she is given a bonus equal to the loan
amount.  K2 Consulting AS has in total purchased 15.500 shares at an average
price of NOK 181,37 per share. After the purchase K2 Consulting AS holds 15.500
Medistim shares.

After these transactions Kari E. Krogstad controls in total 62.583 Medistim
shares. Medistim ASA has 31.117 own shares after the transactions.